🥇 First rule of investing? Know when to save! Up to 55% off InvestingPro before BLACK FRIDAYCLAIM SALE

Benitec launches mid-stage study of BB-401 in HNSCC; shares up 4%

Published 03/05/2018, 01:02 PM
© Reuters.  Benitec launches mid-stage study of BB-401 in HNSCC; shares up 4%
VTRS
-
BNTC
-
  • Thinly traded nano cap Benitec Biopharma (BNTC +4.2%) commences an Australia and Russia-based Phase 2 clinical trial evaluating BB-401 in patients with head and neck squamous cell carcinoma (HNSCC).
  • The open-label 30-subject study will assess the safety, tolerability and efficacy of BB-401 administered via intratumoral injection.
  • According to ClinicalTrials.gov, the estimated primary completion date is April 2019.
  • BB-401 is a recombinant DNA construct that produces an antisense RNA specific to Epidermal Growth Factor Receptor (EGFR). More than 90% of HNSCC lesions overexpress EGFR. BB-401 is designed to inhibit the expression of EGFR which will control cancer progression.
  • Now read: Mylan (NASDAQ:MYL)'s Growth Is Dead


Original article

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.